Why should we worry about the new European Medicines Agency (EMA) pilot project to accelerate the approval of new drugs? James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the October issue Editorial, that looks at the pros and cons of this new trend both in the USA and Europe.

Read the full article here: http://dtb.bmj.com/content/54/10/109.full.

Also in this podcast:

• the use of the new antibiotic Fosfomycin trometamol for the treatment of acute uncomplicated lower urinary tract infections (UTIs) –http://dtb.bmj.com/content/54/10/114.abstract;